- The European Medicines Agency selects Pluristem Therapeutics' (PSTI +1.5%) PLX cell program in critical limb ischemia for its Adaptive Pathways pilot project, the goal of which is to shorten the access time to new therapies. The project allows for early marketing authorization of a new medicine for a restricted patient population, followed by additional assessments and possible subsequent approval for a broader patient population.